BPC-157 vs TB-500: What Each One Actually Does

They get named in the same breath, sold in the same combo vial, and treated online as two brands of the same thing. They are not the same thing. They do different jobs, and the reason the stack is popular is precisely that the jobs are different.

BPC-157 — the local medic

BPC-157 is a 15-amino-acid sequence pulled out of a larger protein found in human gastric juice — a protein your stomach makes to keep itself from digesting its own wall. Researchers isolated the fragment that appeared to carry the protective activity.

What the preclinical literature describes:

• Angiogenesis at the wound site. New capillary growth into damaged tissue.
• Growth-hormone receptor upregulation on tendon fibroblasts, which is the most-cited explanation for the tendon results.
• Nitric oxide pathway modulation.
• Cytokine suppression — interrupting the inflammatory loop that keeps a chronic injury chronic.
• Collagen synthesis.
• It is gastric-stable, which is why an oral liposomal form is plausible for gut pathology specifically, where a systemic peptide would be pointless.

The word doing the work in all of that is local. BPC-157 behaves like something that turns up where the damage is.

TB-500 — the dispatcher

TB-500 is a synthetic 7-amino-acid fragment corresponding to residues 17–23 of native Thymosin Beta-4, acetylated. Two things worth being precise about, because the internet is not:

TB-500 is not TB-4. Thymosin Beta-4 is a 43-amino-acid protein. TB-500 is the short active region of it, isolated and made shelf-stable. If a vendor uses the names interchangeably, that tells you something about the vendor.

What the literature describes:

• Actin upregulation — actin is the scaffolding protein cells use to change shape and move.
• Progenitor cell mobilisation — pulling repair-capable cells out of reservoir tissue and moving them toward damage.
• Angiogenesis, by a different route than BPC-157.
• Inflammation reduction across muscle, tendon, cardiac and neural tissue.

The word doing the work here is systemic. TB-500 behaves like something that tells the body's repair crews where to go.

Why they are stacked

A local repair signal and a systemic mobilisation signal are complementary rather than redundant. The forum framing — one is the medic, one is the dispatcher — is crude but not wrong.

The combined stack is the Recovery Kill, and it is the most-run protocol in this registry by a wide margin.

What the evidence actually is

Be honest about this, because most pages on this topic are not.

Preclinical: substantial. Rat and rabbit tendon, ligament and gut models on BPC-157 going back to the 1990s, with a consistent accelerated-healing signal across labs. TB-500 has an analogous cell-migration and cardiac-repair literature.

Human: thin. There is no large randomised controlled trial of either compound for musculoskeletal injury. What exists is case reports, athlete anecdote, and forum self-report. Neither compound is FDA-approved for human use. Both are on the WADA prohibited list.

That gap between "consistent animal signal" and "no human trial" is the entire reason this registry exists. Structured self-report is not a randomised trial. It is also not nothing, and right now it is the only real-world outcome data anyone is collecting.

If you run either compound, log the cycle. Anonymous, ninety seconds, and it is the only way this category ever gets a real evidence base.

Contraindications worth repeating

Both act on angiogenesis. That makes active malignancy a hard stop until an oncologist clears it — you do not want to be improving blood supply to a tumour. No data in pregnancy or lactation. Stop two weeks before elective surgery.

Full protocol detail, dosing and reconstitution: Recovery Kill and the Wolverine stack.